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ABSTRACT-Objectives. The ratio between free and total prostate-specific antigen (PSA) in serum (F/l ratio) 
was shown to improve the specificity of total serum PSA for the detection of prostate carcinoma in selected 
populations. In this study, the value of the F/l ratio for screening of prostate cancer was compared with that 
of age-specific reference ranges for PSA and PSA density (PSAD) by a simulation experiment. 
Methods. In 1726 men between 55 and 76 years old, 67 prostate carcinomas were detected by applica- 
tion of digital rectal examination (DRE), transrectal ultrasonography (TRUS), and total serum PSA. A serum 
PSA of 4.0 ng/mL or more, an abnormal DRE, or an abnormal TRUS were the indications to perform 308 
biopsies. A simulation was performed in which an F/l ratio of 0.20 (ProStatus PSA Free/Total), age-specific 
PSA reference ranges, and a PSAD of 0.12 ng/mUcc were used to study their capability to increase the speci- 
ficity of total serum PSA in predicting prostate biopsy results. 
Results. Using age-specific PSA reference ranges and DRE as indicators for biopsy, a reduction of 37% (1 13) 
of biopsies would have been obtained with a loss of detected cancers of 12% (1 1). For the use of PSAD and 
DRE, these numbers were 28% (96) and 1 1 O/O (7), respectively. Application of a serum PSA of 4.0 ng/mL or 
more and an F/l ratio of 0.20 or less and an abnormal DRE as indicators for biopsy would reduce the num- 
ber of biopsies by 37% (1 12) and the number of detected cancers by 1 1% (7). The biopsy to prostate can- 
cer ratio of these simulations varied between 3.3 and 3.6. Minimal loss of cancer detection of 3% (2) with a 
reduction in the number of biopsies of 17% (53) is obtained when TRUS is omitted from the screening pro- 
tocol. Selecting men by a total serum PSA value of 2.0 ng/mL for further diagnostic workup by TRUS and DRE 
would have reduced the number of biopsies by 30% (1021, and the number of cancers detected by 6% (4). 
Conclusions. The most cost-effective protocol for screening prostate carcinoma appears to be prescreening 
by total serum PSA. The F/l ratio might be used to detect carcinomas in the PSA range below 4.0 ng/mL, but 
the best threshold remains to be assessed. UROLCGY~ 46: 779-784, 1995. 
S creening for prostate cancer (PC) is usually per- formed by prostate-specific antigen (PSA) and 
digital rectal examination (DRE); transrectal ultra- 
sonography (TRUS) can be added for lesion detec- 
tion and prostate volumetry. Selection of candidates 
for prqstate biopsy is complicated by the fact that 
all screening modalities lack sufficient specificity 
This results in a high ratio between the number of 
biopsies and the number of detected carcinomas. In 
most screening studies, overall about five biopsies 
are needed to detect one carcinoma.1-5 
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Several additional parameters, such as prostate 
volume and age, have been analyzed to reduce 
this ratio, without trying to limit the number of 
carcinomas.6-9 
The free to total serum PSA ratio (F/T ratio) may 
represent a new parameter to increase the speci- 
ficity of total serum PSA to detect PC in selected 
patient+l2 and in a screening population.13 
In this study, a simulated case selection for 
biopsy was performed in a well-defined screening 
population to illustrate the value of F/T ratio, age- 
specific PSA reference ranges,14 and PSA density 
(PSAD)15 for the detection of PC. 
MATERIAL AND METHODS 
In 1726 men from the general population, aged between 55 
and 76 years, serum PSA (DELFIA ProStatus PSA Free/Total; 
Wallac Oy, Finland), and TRUS, were performed. Serum sam- 
ple collection and storage, PSA tests used, the study popula- 
tion, screening tools, and biopsy indications were described 
in a previous publication in this journal13 and in separate 
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TABLE I. Results of simulated case selection for biopsy, based on the results 
by screening with PSA, DRE, and TRUS in 1726 men, of whom 67 men 
with prostate cancer had 308 biopsies (first) line 
Reduction of Loss of 
Biopsies (%) Overall 
Prescreen Biopsy Indicator WI p%? BxlPC 
- PSA > 4, DRE, TRUS - - 4.6 
- PSA > 4, DRE 17 (2.1) 3 (2.1) 3.9 
PSA> 2, PSA > 4, DRE, TRUS 30 (2.6) 6 (2.9) 3.4 
PSA> 2, PSA > 4, DRE 36 (2.8) 6 (2.9) 3.1 
PSA-age PSA > 4, DRE, TRUS 39 (6.0) 
- PSA-age, DRE 37 (2.8) 12 (4.0) 3.3 
PSAD, DRE 28 (2.4) 1 1 * (3.8) 3.6* 
PSA > 4 AND PSAD, DRE 39 (2.8) 1 1 (3.8) 3.2 
PSA > 4 AND F/T, DRE 37 (2.8) 1 1 (3.8) 3.3 
KEY: Bx = biopsy; DRE = abnoml result by digital rectal examination; F/T = free/total PSA ratio 0.20 or fess; PC = prostate cancer; PSA>4 = total sown PSA of 4.0 
nghL or more; PSA-age = total serum PSA larger than age-specific reference range; PSAD = PSA density 0.12 ng/mUcc 01 more; TRUS = lesion detected by tramrectal 
ultrasound. 
*Real incidence of cancels unknown. 
TABLE II. Age, prostatic volumes, and PSA values of 1659 benign and 
6 7 participants with prostate cancer 
Benign Prostate Cancer 
No. Median Range No. Median Range 
Age WI 1659 64.0 54.1-77.0 67 66.8 55.6-76.2 
Total gland volume 1565 30.5 7.7-203.6 64 33.0 16.3-l 05.4 
Transition zone volume 1606 9.3 0.5-l 15.0 63 10.6 3.3-47.2 
Abbott IMx 792 1.2 o-33.5 31 6.3 0.4-93.8 
Hybritech Tandem E 867 1.3 O-29.6 36 7.1 1-156 
DELFIA ProStatus EQM 1659 1.3 0.01-34.9 67 7.2 0.4-l 65.1 
DELFIA ProStatus FT total PSA 1659 1.2 0.01-30.0 67 7.6 0.5-l 49.6 
DELFIA ProStatus FT free PSA 1659 0.33 0.0 l-8.4 67 0.9 0.15-15.6 
studies.16J7 Ultrasound-guided random sextant biopsies were 
performed if the serum PSA level was 4.0 ng/mL and higher, 
or if the DRE was abnormal. When hypoechoic lesions were 
seen by TRUS, biopsy of the lesion was also performed next 
to sextant biopsies. 
Age-specific reference ranges for PSA and F/T ratio were 
constructed14 with the IMx and the ProStatus PSA Free/To- 
tal assays, using the 95th percentile upper limit of values 
(mean value plus 2 standard deviations) in men without 
prostate cancer, to analyze their capacity to distinguish be- 
tween tumor and benign conditions. To allow comparison 
with available literature information, the sera of 188 asymp- 
tomatic blood donors aged 20 to 43 years were also assessed. 
Reference ranges for the age between 44 and 55 years were 
extrapolated from these results. Grouping by age ranges of 5 
years was used to allow for a more continuous spectrum 
compared with age ranges of 10 years.18 
Venn diagrams were used to describe the number of biop- 
sies performed, and the number of cancers detected in the 
population studied and in the simulation procedure. Entry in 
the various simulations was by a total serum PSA of 4.0 
ng/mL and more, an abnormal DRE, an F/T ratio smaller 
than 0.20, a total serum PSA exceeding the constructed age 
reference value, and a PSAD value of 0.12 ng/mI.Icc or more. 
The F/T ratio threshold of 0.20 was chosen, as this value was 
in between the median values of 67 men with and 1659 men 
without PC.” The PSAD threshold was chosen as recom- 
mended by Littrup et c11.,~ who optimalized their original 
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threshold of 0.20 ng/mL/cc in 1991 to a value of 0.12 
ng/mUcc for use in a screening population. Omitting lesion 
detection by TRUS in the various simulations excluded 2 
men with PC, and limited the maximum number of detected 
carcinomas to 65. Also a PSA prescreen value of 2.0 ng/mL 
was evaluated because of the expected cost-effectiveness. Re- 
sults of the various simulations have been summarized, in 
which the standard error (SE) of the calculated reductions in 
biopsies and detected cancers are depicted (Table I>. 
RESULTS 
General characteristics of all men are shown in 
Table II. In 1726 men, 67 cancers were histologi- 
cally diagnosed by 308 sextant prostate biopsies. 
There was no significant difference between the 
median prostate volume of men with and without 
PC. Therefore, no sampling advantage by biopsy 
for smaller prostates occurred.lg 
Figure 1A shows the Venn diagram illustrating 
the distribution of the indications for prostate 
biopsy in 308 men with abnormal DRE, TRUS, or 
a serum PSA value of 4.0 ng/mL or more. In Fig- 
ure lB, the number of cancers found and the 
biopsy (Bx)/PC ratio (between parentheses) is in- 
dicated. The combination of all three screening 
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TABLE III. Age-specific PSA reference ranges: indicated are the upper limits 
(all lower limits are equal to zero) 
Age Range 
40-49 50-54 55-59 60-64 65-69 70-75 
Oesterling et al. l 4 2.5 3.5 4.5 6.5 
Abbott IMx 2.8 3.5 4.0 4.7 5.4 6.3 
ProStatus Total 3.1 3.8 4.3 4.9 5.5 6.3 
ProStatus Free 0.75 0.87 0.96 1.06 1.17 1.29 
Blopsie8 (#). N - 308 Cancers (9. (Biopsies /Cancer). N - 87 
A B 
FIGURE 1. Venn diagrams illustrating the distribution 
of the indications for prostate biopsy in 308 men (A), 
and the number of cancers detected by digital rectal 
examination, TRW, and a serum PSA value of 4.0 
ng/mL or more (B); between parentheses is noted the 
ratio between the number of biopsies performed and 
the number of cancers detected (biopsy/cancer ratio). 
modalities led to the lowest, and most effective, 
Bx/PC ratio of 1.3, while 26.5 biopsies were 
needed to detect one carcinoma when the indica- 
tion for biopsy was a hypoechogenic lesion only 
Overall the Bx/PC ratio was 4.6. 
Table III shows age-specific reference ranges for 
PSA described by Oesterling et al. l4 and those of the 
participants of this study, excluding those men with 
a detected PC. The reference ranges include 95% of 
the serum PSA values per age-group for 1847 men 
(benign participants and donors) without detectable 
PC. The correlation coefficient between age and to- 
tal PSA for all men, including blood donors, was 
0.32, and 0.16 for men aged 50 years or older. For 
the free PSA (ProStatus Free/Total), these correla- 
tions were 0.30 and 0.21, respectively 
In Figure 2 the detected PCs are indicated in re- 
lation to the 95 percentile of the age reference 
ranges for PSA. Organ-confined tumors (n = 59, 
clinically staged) are contrasted with nonorgan 
confined tumors (n = 7), or carcinomas with un- 
known stage (n = 1). A large number of detected 
prostate carcinomas (39%, 20 confined, 2 noncon- 
fined, 1 unknown staging) are found within the 
age-specific reference ranges. The cases are rather 
equally distributed over the age-groups involved. 
FIT RAT10 
Figure 3 shows the simulated case selection for 
biopsy using a PSA value of 4.0 ng/mL or more, an 
abnormal DRE, and an F/T ratio of 0.20 or less as 
a criterion for biopsy Of 494 men who entered 
into this simulation, 263 had biopsies. Of 363 men 
who had an indication for biopsy based on the F/T 
ratio of 0.20 or less, only 132 had biopsies ac- 
cording to the study protocol (Fig. 3A). In the PSA 
range of 4.0 ng/mL and more, the specificity of 
PSA was increased by the application of the F/T 
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FIGURE 2. Relationship be- 
tween total PSA and age of 67 
men with prostate carcinoma; 
the age-specific reference range 
and clinical stage of 66 curci- 
nomas are indicated. 
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FIGURE 3. Venn diagrams showing simulated case se- 
lection for biopsy based on an abnormal digital rectal 
examination, a total serum PSA of 4.0 ng/mL or more, 
and a free to total serum PSA ratio of 0.20 or less; be- 
tween brackets, the number of men selected but with- 
out biopsy is noted (A). The number of positive biopsy 
results and the biopsy/prostate cancer ratio [between 
parentheses) are depicted separately [B). 
,ndicatlon for biopsy (49, N - 255 Cancew (#). (Biopsies / Cancer), N - 65 
A B 
FIGURE 4. Venn diagrams showing simulated case se- 
lection for biopsy based on an abnormal digital rectal 
examination, a total serum PSA of 4.0 ng/mL or more, 
and a higher PSA value than the age-specific reference 
range; between brackets, the number of men selected 
but without biopsy is noted (A). The number of positive 
biopsy results and the biopsy/prostate cancer ratio 
(between parentheses) are depicted separately (B). 
ratio. Using the F/T ratio instead of the total serum 
PSA as an indicator for biopsy in this PSA range, 
five cancers would not have been detected (Fig. 
3B). The number of biopsies decreased from 308 
(Fig. 1A) to 196 (Fig. 3A), a reduction of 37%. 
The overall number of detected carcinomas de- 
creased with 5 + 2 = 7 (11%); the Bx/PC ratio was 
reduced from 4.6 to 3.3. 
AGE-SPECIFICREFERENCERANGES 
Figure 4 shows the simulation procedure using 
a PSA value of 4.0 ng/mL or more, an abnormal 
DRE, and age-specific PSA reference ranges as cri- 
teria for biopsy. There were 255 men entered into 
this simulation. No participants would have been 
selected for biopsy based only on the age-specific 
reference ranges, as all upper limits are above 4.0 
ng/mL. There were 60 men selected for biopsy on 
the basis of a PSA of 4.0 ng/mL only (Fig. 4A). In 
this group, six carcinomas were detected (Fig. 4B). 
Indication for biopsy (#). N - 277 Cancers(X). (Biopsies/Cancer). N - 64 
A B 
FIGURE 5. Venn diagrams showing simulated case se- 
lection for biopsy based on an abnormal digital rectal 
examination, a total serum PSA of 4.0 ng/mL or more, 
and a PSA density of 0.12 ng/mUcc or more; between 
brackets, the number of men selected but without 
biopsy is noted (A). The number of positive biopsy re- 
sults and the biopsy/prostate cancer ratio (between 
parentheses) are depicted separately (B]. 
So, if only age-specific PSA reference ranges were 
used together with an abnormal DRE as indication 
for biopsy, six cancers would not have been de- 
tected. This would have limited the number of 
biopsies from 308 to 195, a reduction of 37%, with 
a Bx/PC ratio dropping from 4.6 to 3.3. The omis- 
sion of TRUS and the use of age-specific reference 
ranges would have induced a loss of 2 + 6 = 8 
(12%) nonpalpable carcinomas. These eight can- 
cers were organ confined. 
PSA DENSITY 
Figure 5 shows the simulated case selection for 
biopsy using a PSA value of 4.0 ng/mL or more, 
an abnormal DRE, and a PSA density of 0.12 
ng/mUcc or more as criteria for biopsy. Of the 
277 men entered into this simulation, 253 had 
biopsies. In 66 of the 67 men with PC, the total 
prostate volume was measured; in 2 of them, can- 
cer was detected only on the base of a hypoecho- 
genie lesion. Therefore, 64 cancers were included 
in Figure 5B. Using PSAD and DRE as indicators 
for biopsy, a reduction in the number of biopsies 
from 308 to 212 was seen (28%), and a loss of 2 
+ 5 = 7 cancers (11%). 
If PSAD was used in the PSA range of 4.0 ng/mL 
or more, together with an abnormal DRE as indi- 
cation for biopsy, five cancers would not have 
been detected (Fig. 5B). This would have limited 
the number of biopsies from 308 to 188, a reduc- 
tion of 39%, with a BflC ratio dropping from 4.6 
to 3.2. A loss of 2 + 5 = 7 (11%) unpalpable car- 
cinomas would occur. These seven cancers were 
organ confined. 
PSAPRESCREEN 
Prescreening accounts for the selection of men 
before being submitted to screening for PC by 
various screening tools, with the possible result of 
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being selected for biopsy A prescreen PSA value 
of 2.0 ng/mL as a threshold for DRE and TRUS 
would give a 70% reduction in the number of 
TRUS investigations, at the price of 6% loss of 
cancers. The number of biopsies (on indication 
PSA 4.0 ng/mL or more, and/or abnormal DRE or 
TRUS) would be reduced by 30%. If TRUS would 
also be omitted, screening of men with a serum 
PSA of 2.0 ng/mL or more with DRE would not 
detect 6% of cancers. The number of biopsies (on 
indication PSA 4.0 ng/mL or more or abnormal 
DRE, or both) would be reduced by 36%. 
SVMMARYOFSIMLJLATIONRESLJLTS 
The main effects of the simulated case selection 
for biopsy are summarized in Table III. Significant 
differences between the various reductions of the 
number of biopsies were seen. 
Concerning the loss of detected cancers, there 
was a significant difference between omitting 
TRUS and the various additions of parameters to 
improve the specificity of a PSA value of 4.0 ng/mL 
and more. 
It was calculated that at least 100 carcinomas 
would be needed to obtain a significant difference 
between a loss of 6% and of 12% of cancers.lg 
COMMENT 
In this screening population of 1726 men who 
all underwent total serum PSA measurement, 
DRE, and TRUS, most of the 67 carcinomas were 
found by sextant biopsies based on the indication 
of PSA or DRE, or both. Only two carcinomas 
were found by TRUS alone. The overall Bx/PC ra- 
tio was 4.6. 
The simulated case selections for biopsy are lim- 
ited by the fact that all biopsies in the present 
study were taken on indication of total serum 
PSA, DRE, or TRUS. Data concerning additional 
parameters are never complete unless all partici- 
pants of the study have biopsies. However, the 
simulation procedure reasonably illustrates what 
may happen to the sensitivity and specificity of a 
combination of tests for the detection of PC. The 
decrease in sensitivity has to be weighed against 
the increase in specificity 
The most cost-effective change of the present 
screening protocol would be to limit the number 
of TRUS procedures or to omit TRUS completely, 
as TRUS is the most time-consuming screening 
modality A prescreen PSA value of 2.0 ng/mL as 
a threshold for DRE and TRUS would give a 70% 
reduction in the number of TRUS investigations, 
at the price of 6% loss of cancers. The number of 
biopsies (on indication of PSA 4.0 ng/mL or more 
or abnormal DRE, or both) would be reduced by 
30%. Screening all men by DRE and PSA only 
would reduce the number of biopsies by 17% 
(Fig. 1) with a loss of 3% of cancers and a Bx/PC 
ratio of 255/65 = 3.9. 
Two parameters were discussed that may im- 
prove the specificity of the combination of total 
serum PSA with DRE without the use of TRUS. 
The most cost-effective is the application of age- 
specific PSA reference ranges. It was seen that this 
parameter decreases the sensitivity considerably: 
12% of carcinomas would have been missed, and 
the number of biopsies were reduced by 37%. This 
is at variance with the study of Oesterling et ~1.~ 
in which 5.5% of 1686 biopsies in an outpatient 
population of 2988 men of 60 years and older 
would have been avoided by the use of age-specific 
reference ranges, and 19 of the 608 cancers (3%) 
would not have been detected. In the study of 
Catalona et ul.,’ who evaluated the effect of age- 
specific reference ranges in a screening study of 
6630 men of 50 years and older, an overall re- 
duction in the number of biopsies of 6% was ob- 
tained, with a loss of 8% of palpable and nonpal- 
pable tumor detection. Both studies concern 
different study populations, without the use of 
TRUS for lesion detection. 
The use of age-specific reference ranges as a 
prescreen value for application of DRE and TRUS 
has to be discouraged, as 39% of cancers would 
have been missed (Fig. 2). These findings are in 
line with our previous observationsZo and those of 
Littrup et a1.,6 who found a loss of 28% of de- 
tectable cancers. 
With a threshold of 0.20, the application of the 
F/T ratio would have induced a large number of 
additional biopsies, especially in the PSA range 
below 4.0 ng/mL. The use of F/T ratio for men 
with a total PSA of 4.0 ng/mL or more or an ab- 
normal DRE would miss 11% of cancers and re- 
duce the number of biopsies by 37%. According 
to Colberg et al., 21 there is a 7.9% incidence of 
carcinomas in the PSA range between 2.9 and 4.0 
ng/mL. It can be estimated by extrapolation that 
in the 328 men with a PSA range of 2.0 to 4.0 
ng/mL in the present study 23 cancers would have 
been found by sextant routine biopsies, whereas 
actually 10 were detected. The value of the F/T ra- 
tio can be tested if one is willing to biopsy all men 
with a PSA of 2.0 ng/mL or more. The number of 
biopsies would increase from 308 to 506, with an 
overall change of Bx/PC ratio of 4.6 to an esti- 
mated 506/80 = 6.3. 
PSAD as an indicator for biopsy instead of a 
PSA value of 4.0 ng/mL or more, and in combi- 
nation with DRE, has been reported to be more 
cost-effective than age-specific PSA reference val- 
ues.6 In that evaluation of 2930 men recruited to 
a screening study, Littrup et ~1.~ recommended a 
“tailored biopsy approach” using PSAD with a 
threshold of 0.12 ng/mUcc in combination with 
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DRE, in which the number of biopsies were re- 
duced with 15.7% at the price of a loss of 3.6% of 
the cancers. In the present simulation, these num- 
bers for the use of PSAD were larger, respectively, 
28% and 11%. The larger number of undetected 
carcinomas might be due to the included effect of 
omitting TRUS for lesion detection and the as- 
sumption that no cancers would have been de- 
tected by biopsies on the indication of PSAD only 
CONCLUSIONS 
Minimal loss of cancer detection of 3% with a 
reduction in the number of biopsies of 17% is ob- 
tained when TRUS is omitted from a screening 
protocol in which a PSA value of 4.0 ng/mL and 
more, an abnormal DRE, or an abnormal TRUS 
are used as indicators for biopsy 
Age-specific PSA reference ranges, an F/T ratio 
with a threshold of 0.20, and a PSAD with a thresh- 
old of 0.12 ng/mUcc may all reduce the number 
of biopsies with approximately 35% in this study, 
with a reduction in cancer detection of 11%. 
The value of F/T ratio for screening for PC has 
not yet been assessed optimally: especially in the 
PSA range below 4.0 ng/mL, a threshold needs to 
be established for discriminating between benign 
and malignant disease. 
The most cost-effective protocol for screening 
PC appears to be prescreening by total serum PSA 
and exclusion of DRE and TRUS with PSA values 
of 2.0 ng/mL or less. 
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